| Original language | English |
|---|---|
| Pages (from-to) | 429-433 |
| Journal | British Journal of Haematology |
| Volume | 182 |
| Issue number | 3 |
| Early online date | 23 Jun 2017 |
| DOIs | |
| Publication status | Published - Aug 2018 |
Keywords
- Letter
- chronic lymphocytic leukaemia
- mantle cell lymphoma
- DNA damage
- olaparib
Access to Document
- Pratt_et_al_A_multi-centre_phase_I_trial_British_Journal_of_Haematology_2017
This is the peer reviewed version of the following article: Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P. and Stankovic, T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. doi:10.1111/bjh.14793, which has been published in final form at 10.1111/bjh.14793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Accepted author manuscript, 97.7 KBLicence: Other (please specify with Rights Statement) - Pratt_et_al_A_multi-centre_phase_I_trial_British_Journal_of_Haematology_2017_Additional_documents_1
This is the peer reviewed version of the following article: Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P. and Stankovic, T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. doi:10.1111/bjh.14793, which has been published in final form at 10.1111/bjh.14793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Accepted author manuscript, 15.4 KBLicence: Other (please specify with Rights Statement) - Pratt_et_al_A_multi-centre_phase_I_trial_British_Journal_of_Haematology_2017_Additional_documents_2
This is the peer reviewed version of the following article: Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P. and Stankovic, T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. doi:10.1111/bjh.14793, which has been published in final form at 10.1111/bjh.14793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Accepted author manuscript, 28.9 KBLicence: Other (please specify with Rights Statement)
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: British Journal of Haematology, Vol. 182, No. 3, 08.2018, p. 429-433.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma
AU - Pratt, Guy
AU - Yap, Christina
AU - Oldreive, Ceri
AU - Slade, Daniel
AU - Bishop, Rebecca
AU - Griffiths, Mike
AU - Dyer, Martin J S
AU - Fegan, Chris
AU - Oscier, David
AU - Pettitt, Andrew
AU - Matutes, Estella
AU - Devereux, Stephen
AU - Allsup, David
AU - Bloor, Adrian
AU - Hillmen, Peter
AU - Follows, George
AU - Rule, Simon
AU - Moss, Paul
AU - Stankovic, Tatjana
PY - 2018/8
Y1 - 2018/8
KW - Letter
KW - chronic lymphocytic leukaemia
KW - mantle cell lymphoma
KW - DNA damage
KW - olaparib
U2 - 10.1111/bjh.14793
DO - 10.1111/bjh.14793
M3 - Letter
C2 - 28643365
SN - 0007-1048
VL - 182
SP - 429
EP - 433
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -